GlassScriptPhysician profile
Salma Asous
NPI 1275038630
$771.09
in general payments reported to CMS, 2019-2025
11 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.40 · 2022: $29.79 · 2023: $280 · 2024: $240 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $255.71 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $120.66 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $98.58 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $97.43 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $51.31 | 2025 | Nexletol |
| Pfizer INC. | $43.25 | 2021-2024 | |
| Abbvie INC. | $38.98 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $18.62 | 2024 | Airsupra |
| Amgen INC. | $17.20 | 2025 | Repatha, Otezla |
| Dynavax Technologies Corporation | $14.89 | 2023 | Heplisav-B |
| Glaxosmithkline, LLC. | $14.46 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salma Asous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.